

3. Fernández-Díaz C, Castañeda S, Melero R, Loricera R, Ortiz-Sanjuán F, Jun-Mas A, et al. Interstitial lung disease: national multicenter study of 263 patients. *Ann Rheum Dis.* 2020;79 Suppl 1:968.
4. Mochizuki T, Ikari K, Yano K, Sato M, Ozakaki K. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. *Modern Rheumatol.* 2017;29:413–7.
5. Nokhatha SA, Harrington R, Conway R. Is methotrexate contra-indicated in lung involvement of rheumatoid arthritis? *Joint Bone Spine.* 2020;87:535–7. <http://dx.doi.org/10.1016/j.jbspin.2020.06.007>.
6. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon W, Palmer WR. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356–64.
7. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. *J Rheumatol.* 1995;22:1043–7.
8. Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby T, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. *BMJ Open.* 2013;3:e003132.

Luis Arboleya-Rodríguez,<sup>a,\*</sup> Miguel Arias-Guillén<sup>b,c,d</sup>,  
Comité de Neumopatías Intersticiales del HUCA

<sup>a</sup> *Comité multidisciplinar de Neumopatías intersticiales, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain*

<sup>b</sup> *Servicio de Neumología, Hospital Universitario Central de Asturias, Facultad de Medicina de la Universidad de Oviedo, Oviedo, Asturias, Spain*

<sup>c</sup> *Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Asturias, Spain*

<sup>d</sup> *CIBER-Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain*

\* Corresponding author.

E-mail address: [arboleya@ser.es](mailto:arboleya@ser.es) (L. Arboleya-Rodríguez).

<https://doi.org/10.1016/j.reuma.2020.10.009>

2173-5743/ © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

### Neurobehçet's. Comment: "Neuro-Behçet Disease in the Central University Hospital of Asturias"



#### Neurobehçet's. Comentario: "La enfermedad de Neuro-Behçet en el Hospital Universitario Central de Asturias"

Dear Editor,

We read with great interest the manuscript by Charca-Benavente et al., about a frequency and profile of patients with neuro-Behçet's disease at the Central University Hospital of Asturias over a period of 37 years.<sup>1</sup> We have the following comments.

Neurological manifestations, found in 10–30% of the patients with Behçet disease, are recognized in the medical literature as Neurobehçet (NB), were described for the first time in 1941 by Knapp, and in 1954 Cavara & DÉRmo coined the term NB, and include migraine-like headache, aseptic meningoencephalitis, encephalopathy, dementia, seizures, cranial nerve and bulbar palsy, movement disorders, cerebellar ataxia, myelopathy, neuromuscular hearing loss, stroke, psychiatric disturbances, and a multiple sclerosis-like picture.<sup>2</sup> They usually manifest within 5 years of onset. Neurological complications progress to severe disability, with a high mortality rate.<sup>3</sup> Although this broad spectrum of manifestations is widely recognized, myositis is rare.

However, in the study by Charca-Benavente et al., despite a considerable period of analysis, it strikes us that there were no cases of muscle involvement, so we would like to know to what the authors attribute this data.

The authors should have addressed the neuromuscular manifestations of NB. NB must be considered as a differential diagnosis of localized or generalized inflammatory muscle disorders especially

when findings of multiple tissue and organ lesions or any symptom of the characteristic triad are present. Given the multisystemic nature of the syndrome, it's not surprising the report of "unusual" manifestations that will further expand the wide spectrum of NB.<sup>2</sup>

We are grateful to the authors for the excellent article addressing a relevant topic within BD, allowing discussion to contribute with knowledge.

### References

1. Charca-Benavente LC, Gómez de la Torre R, Caminal-Montero L, Coto-Hernández R, Colunga-Argüelles D. Neuro-Behçet Disease in the Central University Hospital of Asturias. *Reumatol Clin.* 2021;17:32–6. <http://dx.doi.org/10.1016/j.reuma.2019.03.005>.
2. Rodríguez CA, Fustes OJH, Munhoz RP, Fustes OJH. Polymyositis in Adamantiades-Behçet's disease. *Int J Neurol Neurother.* 2020;7:094. <http://dx.doi.org/10.23937/2378-3001/1410094>.
3. Pearce JMS. Neurological symptoms of Adamantiades-Behçet's syndrome. *J Neurol Neurosurg Psychiatry.* 2006;77:956–7. <http://dx.doi.org/10.1136/jnnp.2006.093971>.

Otto J. Hernandez Fustes<sup>a,\*</sup> Carlos Arteaga Rodriguez<sup>b</sup>

<sup>a</sup> *Complexo Hospital de Clinicas-Universidade Federal do Paraná, Serviço de Neurologia, Serviço de Doenças Neuromusculares, Curitiba, PR, Brazil*

<sup>b</sup> *Universidade Positivo, Curitiba, PR, Brazil*

\* Corresponding author.

E-mail address: [Otto.fustes@hc.ufpr.br](mailto:Otto.fustes@hc.ufpr.br) (O.J. Hernandez Fustes).

<https://doi.org/10.1016/j.reuma.2021.02.001>

1699-258X/ © 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.